Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.74 |
| ▸ | PDE4A | P27815 | 12/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450501 | 0.91 | PDE4D (0.75) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL202816 | 0.90 | PDE4D (0.74) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7424332 | 0.87 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7450727 | 0.85 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL201172 | 0.83 | PDE4D (0.84) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7424626 | 0.82 | PDE4A (0.66) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL8323597 | 0.82 | PDE4A (0.66) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL201574 | 0.81 | PDE4D (0.74) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7458162 | 0.77 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7568142 | 0.76 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020055543-A1 | N-(aroyl)glycine hydroxamic acid derivatives and related compounds | KLEINMAN EDWARD F (US) | 2002-05-09 | — | — | US | claimed |
| EP-0850215-B1 | N-(AROYL)GLYCINE HYDROXAMIC ACID DERIVATIVES AND RELATED COMPOUNDS | PFIZER (US) | 2000-10-18 | — | — | EP | claimed |
| US-20020055543-A1 | N-(aroyl)glycine hydroxamic acid derivatives and related compounds | KLEINMAN EDWARD F (US) | 2002-05-09 | — | — | US | disclosed |
| EP-0850215-B1 | N-(AROYL)GLYCINE HYDROXAMIC ACID DERIVATIVES AND RELATED COMPOUNDS | PFIZER (US) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055543-A1 | N-(aroyl)glycine hydroxamic acid derivatives and related compounds | PTGS1, IL4I1, PTGIS | PDE4D 487/4885PDE4A 73/4885PDE4B 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.